Syk has been shown to regulate Sp1 transcription factor activity in breast cancer cells; therefore, loss of syk may predispose breast epithelial cells to ErbB2-mediated downregulation of α2 integrin, resulting in a further step along the progression pathway. This evidence concerns the gene ERBB2 and breast carcinoma.